Recent news on Vitrase

ISTA reports 91% increase in first quarter revenue  -  Apr 26, 2007
OSN SuperSite (subscription),Revenue from sales of Istalol (timolol maleate 0.5%) increased 29% to total $2.2 million, while revenue from Vitrase (hyaluronidase) sales increased 25% to

ISTA Pharmaceuticals Reports First Quarter 2007 Financial Results  -  26 Apr 2007
PR Newswire (press release),...except percentage data) Quarter Ended Quarter Ended March 31, 2007 March 31, 2006 % Change Xibrom $7.0 $2.8 150 % Istalol 2.2 1.7 29 % Vitrase 1.0 0.8

Innovative biomed companies woo investors  -  Mar 1, 2007
Orange County Register,Irvine-based Ista Pharmaceuticals once had high hopes for the drug Vitrase, but "we've never found a cost-effective pathway to bring it to market," Lauren

ISTA Pharmaceuticals Reports 2006 Financial Results  -  Mar 6, 2007
PR Newswire (press release),...except percentage data) Year-Ended Year-Ended December 31, 2006 December 31, 2005 % Change Xibrom $20.2 $5.3 281% Istalol 8.3 2.6 219% Vitrase 4.2 2.5

An eye for innovation  -  Dec 14, 2006
OCRegister,So far, the Ista pipeline has carried three products to market – Xibrom, once-a-day Istalol for glaucoma patients, and Vitrase, which helps injected drugs

ISTA Pharmaceuticals Reports Third Quarter 2006 Financial Results ...  Nov 2, 2006
Net product sales for the third quarter of 2006 included Xibrom(TM) net sales of $5.6 million, Istalol® net sales of $2.0 million, and Vitrase® net sales of ... -Yahoo! News (press release) FASTEST GROWING COMPANIES  Oct 21, 2006
Ista’s seen its sales grow thanks to the commercialization of its first three drugs, Istalol, Vitrase and Xibrom, all of which have come out during the past ... -Orange County Business Journal, ISTA Pharma Q2 Loss Narrows On Higher Revenue -Update  Aug 3, 2006
...second quarter. Net product sales for the second quarter-included Xibromnet sales, Istalol sales and Vitrase sales. The company's ... -Trading Markets

ISTA Pharmaceuticals Narrows 2Q Loss  Aug 3, 2006
...million. Glaucoma drug Istalol registered sales of $2.1 million and spreading agent Vitrase brought in sales of $1.1 million. Wall ... -Houston Chronicle

ISTA Pharmaceuticals' Second Quarter 2006 Financial Results ...  Aug 3, 2006
Net product sales for the second quarter of 2006 included Xibrom(TM) net sales of $4.3 million, Istalol® net sales of $2.1 million, and Vitrase® net sales of ... -Yahoo! News



ISTA Pharmaceuticals Reports Simple Model Predicts Treatment ...  May 1, 2006
...today details of two scientific poster presentations that describe the first predictive model for treatment success with Vitrase® (Ovine Hyaluronidase) in ... - Yahoo! News

ISTA Pharmaceuticals, Inc. Reports First Quarter 2006 Financial ...  May 8, 2006
Net product sales for the first quarter of 2006 included Xibrom(TM) net sales of $2.9 million, Istalol® net sales of $1.8 million and Vitrase® net sales of ... - Yahoo! News

ISTA Pharmaceuticals Q1 Net Loss Widens Despite Higher Revenues ...  May 8, 2006
The fee is attributable to recognition of license fee payment received from Otsuka Pharmaceutical Co. for the license for Vitrase in Japan. ... - Trading Markets

Allergan Reports First Quarter Operating Results; Pharmaceutical ...  May 3, 2006
...of $15.7 million and the tax effect for non-GAAP adjustments of $5.3 million (h) Transition/duplicate operating expenses (i) ISTA Vitrase collaboration fee (j ... - Genetic Engineering News

(PRN) - Webcast Alert: Perceptron, Inc. Announces Third Quarter ...  May 1, 2006
...[+]. (PRN) - ISTA Pharmaceuticals Reports Simple Model Predicts Treatment Success With Vitrase(R) in Vitreous Hemorrhage Associated With Diabetes ... [+. ... - Bolsamania.com





ISTA Pharmaceuticals, Inc. Reports Fourth Quarter and Year End ...  Feb 23, 2006
Net product sales for the fourth quarter 2005 included Xibrom(TM) net sales of $1.5 million, Istalol(R) net sales of $1.4 million and Vitrase(R) net sales of ... - PR Newswire,

ISTA Pharmaceuticals Announces Acceptance of ISTA's European ...  Jan 12, 2006
Vitragan is ISTA's proprietary formulation of highly purified ovine hyaluronidase which is commonly known in the US as Vitrase(R). A vitreous hemorrhage occurs ... - PR Newswire

ISTA's eye treatment under EU review  Jan 12, 2006
12 Jan 2006, 17:44 GMT - Vitragan is ISTA's proprietary formulation of highly purified ovine hyaluronidase, which is commonly known in the US as vitrase. ... - Pharmaceutical Business Review

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional